Drug Trial Radar · NCT04880876
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
124
Planned (sponsor's estimate)
Start
Aug 13, 2021
Primary completion
Dec 2032
Study completion Dec 2032
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
Conditions
- Irritable Bowel Syndrome
Interventions
25mg EluxadolineDrug
Oral Tablets
100mg EluxadolineDrug
Oral Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse EventsTime frame: 52 weeks
- Percentage of Participants with Clinically Significant Laboratory Values (clinical chemistry, complete blood count, urinalysis) as assessed by the InvestigatorTime frame: 52 weeks
- Percentage of Participants with Clinically Significant ECGs as assessed by the InvestigatorTime frame: 52 weeks
- Percentage of Participants with Clinically Significant vital sign measurements as assessed by the InvestigatorTime frame: 52 weeks
- Percentage of Participants with any new Physical examination abnormality or worsening of change from baselineTime frame: 52 weeks
- Percentage of Participants with any new neurological abnormality post baseline or worsening of change from baselineTime frame: 52 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Kindred Medical Institute, LLC /ID# 227595
Corona, California
Valencia Medical & Research Center /ID# 246221
Miami, Florida
Florida Research Center, Inc. /ID# 227597
Miami, Florida
Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 227600
Stockbridge, Georgia
IPS Research Company /ID# 227594
Oklahoma City, Oklahoma
Preferred Primary Care Physicians, Inc. /ID# 227596
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.